Novo Nordisk 1st-qtr 2010 sales growth driven by modern insulins and Victoza
Danish insulin giant Novo Nordisk reported first-quarter 2010 financial results ahead of consensus forecasts, helped by stocking of its new, once-daily diabetes drug Victoza (liraglutide) and non-recurring income, posting a net profit increase of 23% to 3.32 billion Danish kroner ($596.8 million) and earnings per share (diluted) up 27% to 5.61 kroner.
Sales for the three months rise 9% to 13.67 billion kroner, with turnover at Novo's diabetes division rising 11% to 10.15 billion kroner. The company said that turnover of its 'modern' insulin products, including Levemir (insulin detemir) and NovoRapid (insulin aspart) contributed 5.86 billion kroner, a rise of 17%. However, revenues from human insulins fell 8% to 2.77 billion kroner, and oral antidiabetics decreased 7% to 645 million kroner. The company posted total first-quarter revenue of 370 million kroner for Victoza.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
| Headless Content Management with Blaze